➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
Express Scripts
Merck
Colorcon
Mallinckrodt
Harvard Business School

Last Updated: August 8, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ASCORBIC ACID

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

505(b)(2) Clinical Trials for Ascorbic Acid

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
New Dosage NCT01533090 Evaluation of Reduced-volume PEG Bowel Preparation Administered the Same Day of Colonoscopy Completed Catholic University of the Sacred Heart N/A 2010-04-01 The conventional total dose of 4 L of polyethylene glycol (PEG) given the day before the procedure is safe and effective. It has been the standard cleansing regimen for the last 25 years. To overcome the difficulty in completing the bowel preparation due to large volume and/or taste, reduced-volume (mixed) bowel preparation of bisacodyl and 2 L of PEG have been shown to provide adequate colon cleansing and better tolerability. LoVol-esse is a reduced-volume PEG-based bowel preparation to be used in combination with bisacodyl and designed to improve patient tolerability and attitude toward bowel cleansing prior to colonoscopy thanks to the reduced volume and improved taste. The present study is intended to compare the new dosing regimen of the bowel lavage solution given the same day compared with standard PEG formulation (SELG 1000) given the day before colonoscopy.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for Ascorbic Acid

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000595 Evaluation of Subcutaneous Desferrioxamine as Treatment for Transfusional Hemochromatosis Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 2 1978-01-01 To determine whether deferoxamine prevented the complications of transfusional iron overload.
NCT00006021 Arsenic Trioxide Plus Vitamin C in Treating Patients With Recurrent or Refractory Multiple Myeloma Completed National Cancer Institute (NCI) Phase 1/Phase 2 2000-06-01 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Vitamin C may increase the effectiveness of arsenic trioxide by making cancer cells more sensitive to the drug. PURPOSE: Phase I/II trial to determine the effectiveness of arsenic trioxide plus vitamin C in treating patients who have recurrent or refractory multiple myeloma.
NCT00006021 Arsenic Trioxide Plus Vitamin C in Treating Patients With Recurrent or Refractory Multiple Myeloma Completed University of Miami Phase 1/Phase 2 2000-06-01 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Vitamin C may increase the effectiveness of arsenic trioxide by making cancer cells more sensitive to the drug. PURPOSE: Phase I/II trial to determine the effectiveness of arsenic trioxide plus vitamin C in treating patients who have recurrent or refractory multiple myeloma.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Ascorbic Acid

Condition Name

Condition Name for Ascorbic Acid
Intervention Trials
Colonoscopy 7
Sepsis 7
Multiple Myeloma 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Ascorbic Acid
Intervention Trials
Multiple Myeloma 13
Pancreatic Neoplasms 12
Neoplasms, Plasma Cell 11
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Ascorbic Acid

Trials by Country

Trials by Country for Ascorbic Acid
Location Trials
United States 100
Korea, Republic of 20
Spain 11
Italy 6
China 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Ascorbic Acid
Location Trials
Pennsylvania 9
New York 8
California 7
Arizona 7
Florida 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Ascorbic Acid

Clinical Trial Phase

Clinical Trial Phase for Ascorbic Acid
Clinical Trial Phase Trials
Phase 4 26
Phase 3 30
Phase 2/Phase 3 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Ascorbic Acid
Clinical Trial Phase Trials
Completed 64
Not yet recruiting 41
Recruiting 30
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Ascorbic Acid

Sponsor Name

Sponsor Name for Ascorbic Acid
Sponsor Trials
National Cancer Institute (NCI) 14
Thomas Jefferson University 7
Cephalon 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Ascorbic Acid
Sponsor Trials
Other 250
Industry 31
NIH 21
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Merck
Harvard Business School
Boehringer Ingelheim
Dow
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.